Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Merck Alzheimer's drug fails in 1 study; another continues

CJME Tuesday, 14 February 2017
*By The Canadian Press*

KENILWORTH, N.J. — Merck & Co. will stop its study of an experimental Alzheimer's drug in people with mild or moderate symptoms because interim results showed "virtually no chance" of any benefit.

However, the drugmaker said Tuesday it will continue another study of the drug, verubecestat, in patients who don't yet show symptoms. They have some memory problems, but can still perform daily activities.

The two studies were intended to enable Merck to seek regulators' approval... // Read Full Article
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 
Source: Wochit News - < > Embed

News video: Scientists Disappointed After New Alzheimer's Drug Failed

Scientists Disappointed After New Alzheimer's Drug Failed 00:35

Researchers found that the new promising Alzheimer’s drug verubecestat did not work. Dr. Roger Perlmutter, president of Merck Research Laboratories, stated, “While we are disappointed that a benefit was not observed in this study, our work continues [to study the impact of] verubecestat in people...

You Might Like


Other recent news in World

U.S. to recommend Keystone XL PIPELINE approval, sources sayLondon terror: Inside Birmingham flat where KHALID MASOOD lived as he plotted attack
Trump: Pass Health Care Friday, or OBAMACARE StaysHONG KONG election: The nanny, Mr Pringles or the judge?
Inspection SCANDAL makes mincemeat of Brazil's export tradeFin24.com | WIKILEAKS releases CIA hacks of Apple Mac computers
House sets risky HEALTH CARE vote after Trump demands itSYDNEY teenager pleads guilty to Anzac Day terror plot
DEVIN NUNES apologises to Democrats for surveillance briefingSOUTH CHINA SEA installations &#039;primarily&#039; civilian: Li Keqiang

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+